Curaleaf, a prominent international cannabis operator, has completed the full acquisition of Four 20 Pharma, one of Germany’s established medical cannabis operators. This strategic move brings the EU-GMP and GDP-licensed entity entirely in-house for Curaleaf according to a report by Cannabis Business Times.
Regulatory Compliance and Market Access
The company holds both EU-Good Manufacturing Practice (EU-GMP) and Good Distribution Practice (GDP) licenses.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
